Sanofi Has To Do Something

The problems facing French drug giant Sanofi-Aventis (NYSE:SNY) these days are nothing out of the ordinary for the big-cap pharmaceutical sector. The company is facing some major generics competition and has very little in the way of potential blockbusters to immediately replace that revenue. On top of that, Wall Street's growth addiction has left the shares languishing.

The question now, though, is what Sanofi's management is going to do about it. Whatever decisions they make are going to have a tremendous influence on whether shareholders can wait patiently for this stock to recover.


To read the full piece:
http://stocks.investopedia.com/stock-analysis/2010/Sanofi-Has-To-Do-Something-SNY-GENZ-SHPGY-ISIS-GILD-BIIB-HGSI0730.aspx